After 13-year review, FDA finalizes ‘clear, conspicuous and neutral’ drug advertising rule

Today, more than a decade after Congress required the FDA to publish such a regulation, the FDA finalized a rule that will require direct-to-consumer drug advertisements to ensure that the “major statement” of drug risks and side effects is presented in a “clear, conspicuous, and neutral manner.” The changes, which should take effect in mid-2024, should result in drug ads with fewer distracting elements and more emphasis on the major risks of the drug.

Fill out the form to read the full article.

Required *

Copy link
Powered by Social Snap